Indoleamine 2, 3-Dioxgenase Transfected Mesenchymal Stem Cells Induce Kidney Allograft Tolerance by Increasing the Production and Function of Regulatory T Cells

Transplantation

Volumn 99, Issue 9, 2015, Pages 1829-1838

  He, Yue ^a   Zhou, Shan ^a   Liu, Hong ^a   Shen, Bingbing ^a   Zhao, Hongwen ^a   Peng, Kanfu ^a   Wu, Xiongfei ^a  

^a SOUTHWEST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; BIOLOGICAL MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL STIMULATION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; GENETIC TRANSFECTION; GRAFT SURVIVAL; IDO GENE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; JAPANESE WHITE (RABBIT); KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LENTIVIRINAE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MOLECULAR DYNAMICS; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION; WILD TYPE; ADVERSE EFFECTS; ALLOGRAFT; ANIMAL; CELL COMMUNICATION; CELL CULTURE; CELL PROLIFERATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; GRAFT REJECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PROCEDURES; RABBIT; SKIN TRANSPLANTATION; TIME; TRANSPLANTATION TOLERANCE;

ALLOGRAFTS; ANIMALS; BIOLOGICAL MARKERS; CELL COMMUNICATION; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC VECTORS; GRAFT REJECTION; GRAFT SURVIVAL; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KIDNEY TRANSPLANTATION; LENTIVIRUS; LYMPHOCYTE ACTIVATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; RABBITS; SKIN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSFECTION; TRANSPLANTATION TOLERANCE;

EID: 84946921635     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000856     Document Type: Article

References (38)

1. Wolfe RA, Roys EC, Merion RM. Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant. 2010;10: 961-972.
2. Atoui R, Chiu RC. Concise review: immunomodulatory properties of mesenchymal stem cells in cellular transplantation: update, controversies, and unknowns. Stem Cells Transl Med. 2012;1:200-205.
3. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57:11-20.
4. González MA, Gonzalez-Rey E, Rico L, et al. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum. 2009;60:1006-1019.
5. Casiraghi F, Noris M, Remuzzi G. Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. Curr Opin Organ Transplant. 2010;15:731-737.
6. Solari MG, Srinivasan S, Boumaza I, et al. Marginal mass islet transplantation with autologous mesenchymal stemcells promotes long-termislet allograft survival and sustained normoglycemia. J Autoimmun. 2009;32: 116-124.
7. Jia Z, Jiao C, Zhao S, et al. Immunomodulatory effects of mesenchymal stem cells in a rat corneal allograft rejection model. Exp Eye Res. 2012; 102:44-49.
8. Cohen JA. Mesenchymal stem cell transplantation in multiple sclerosis. J Neurol Sci. 2013;333:43-49.
9. Mielcarek M, Storb R, Georges GE, et al. Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2011;17:214-225.
10. Eggenhofer E, Renner P, Soeder Y, et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol. 2011;25:141-147.
11. Zhang W, Qin C, Zhou Z. Mesenchymal stem cells modulate immune responses combined with cyclosporine in a rat renal transplantation model. Transplant Proc. 2007;10:3404-3408.
12. Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006;108: 2114-2120.
13. Eliopoulos N, Stagg J, Lejeune L, et al. Allogeneicmarrow stromal cells are immune rejected byMHC class I-and class II-mismatched recipientmice. Blood. 2005;106:4057-4065.
14. Plumas J, Chaperot L, Richard MJ, et al. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia. 2005;19:1597-1604.
15. Perico N, Casiraghi F, Gotti E, et al. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int. 2013;26:867-878.
16. DahlkeMH, HoogduijnM, Eggenhofer E, et al. Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation. 2009;88:614-619.
17. Tan J,WuW, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA. 2012;307:1169-1177.
18. Shi M, Liu ZW, Wang FS. Immunomodulatory properties and therapeutic application ofmesenchymal stem cells. Clin Exp Immunol. 2011;164:1-8.
19. Chung DJ, Rossi M, Romano E, et al. Indoleamine 2, 3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood. 2009;114:555-563.
20. Jürgens B, Hainz U, Fuchs D, et al. Interferon-?-triggered indoleamine 2, 3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic Tcells. Blood. 2009;114:3235-3243.
21. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008;222: 206-221.
22. Mellor AL, Munn DH. IDOexpression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762-774.
23. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103:4619-4621.
24. Ren G, Su J, Zhang L, et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells. 2009;27: 1954-1962.
25. National Research Counci (US) institute for Labortaory Animal Research, Guide for the care and use of laboratory animals. National Academies Press (US). 1996.
26. Liu X, Peng X, Hu Z, et al. Effects of over-expression of ANXA10 gene on proliferation and apoptosis of hepatocellular carcinoma cell line HepG2. J Huazhong Univ Sci Technolog Med Sci. 2012;32:669-674.
27. Comite P, Cobianchi L, Avanzini M, et al. Isolation and ex vivo expansion of bone marrow-derived porcine mesenchymal stromal cells: potential for application in an experimentalmodel of solid organ transplantation in large animals. Transplant Proc. 2010;4:1341-1343.
28. Pischiutta F, D'Amico G, Dander E, et al. Immunosuppression does not affect human bone marrow mesenchymal stromal cell efficacy after transplantation in traumatized mice brain. Neuropharmacology. 2014;79: 119-126.
29. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713-723.
30. Mellor AL, Chandler P, Baban B, et al. Specific subsets ofmurine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2, 3 dioxygenase. Int Immunol. 2004;16: 1391-1401.
31. Kang SM, Tang Q, Bluestone JA. CD4+ CD25+ regulatory Tcells in transplantation: progress, challenges and prospects. Am J Transplant. 2007;7: 1457-1463.
32. Plain KM, Verma ND, Tran GT, et al. Cytokines affecting CD4(+) T regulatory cells in transplant tolerance. Interleukin-4 does not maintain alloantigen specific CD4(+)CD25(+) Treg. Transpl Immuol. 2013;29:51-59.
33. Bruce MH, Giang TT, Nirupama DV, et al. Do natural T regulatory cells become activated to antigen specific Tregulatory cells in transplantation and in autoimmunity? Front Immunol. 2013;4:208.
34. Liu XJ, Zhang JF, Sun B, et al. Reciprocal effect ofmesenchymal stem cell on experimental autoimmune encephalomyelitis is mediated by transforming growth factor-? and interleukin-6. Clin Exp Immunol. 2009;158: 37-44.
35. Walker LS. Treg and CTAL-4: Two intertwining pathways to immune tolerance. J Autoimmun. 2013;45:49-57.
36. Sudipta T, Indira G. Role of PD1/PDL1 pathway, and TH17 and treg cells in maternal tolerance to the fetus. Biomed J. 2015;38:25-31.
37. Liu H, Bakthavastalam R, Meng Z, et al. PD-L1 signal on liver dendritic cells is critical for Foxp3 + CD4 + CD25+ Treg and liver tolerance induction in mice. Transplant Proc. 2013;45:1853-1855.
38. McClymont SA, Putnam AL, Lee MR, et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. 2011;186:3918-3926.